Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xia Yu
Observed name:
X. Yu
Institutions:
Zhongshan City Second People's Hospital,
Zhongshan People's Hospital
Observed institutions:
Zhongshan City Second People's Hospital,
Zhongshan People's Hospital
ORCID:
0000-0002-7701-2822
Observed ORCID:
0000-0002-7701-2822
OpenAlex ID:
A5021856253
Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial
2024
·
Wen-Jie Chen
, Xia Yu
, et al.
·
Journal of Clinical Oncology
·
38
PDF
Circulating DNA genome-wide fragmentation in early detection and disease monitoring of hepatocellular carcinoma
2024
·
Shifeng Lian
, Chenyu Lu
, et al.
·
iScience
·
7
Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
2024
·
Shifeng Lian
, Chenyu Lu
, et al.
·
Clinical Cancer Research
·
6
Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025
·
Jiali Quan
, Chunlan Zhuang
, et al.
·
Cancer Epidemiology Biomarkers & Prevention
·
3
Early Detection and Disease Monitoring of Hepatocellular Carcinoma Using Circulating Telomere DNA
2022
·
Zongli Zheng
, Shifeng Lian
, et al.
·
Research Square
·
2
PDF
Tertiary lymphoid structures: Defining immune subtypes and enabling precision immunotherapy in nasopharyngeal carcinoma
2025
·
Fan Liu
, Lei Xiong
, et al.
·
Clinical and Translational Discovery
PDF
Supplementary Table S2 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025
·
Jiali Quan
, Chunlan Zhuang
, et al.
PDF
Supplementary Figure S1 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025
·
Jiali Quan
, Chunlan Zhuang
, et al.
PDF
Supplementary Figure S3 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025
·
Jiali Quan
, Chunlan Zhuang
, et al.
PDF
Supplementary Table S4 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025
·
Jiali Quan
, Chunlan Zhuang
, et al.
PDF
Supplementary Table S5 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025
·
Jiali Quan
, Chunlan Zhuang
, et al.
PDF
Supplementary Table S1 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025
·
Jiali Quan
, Chunlan Zhuang
, et al.
PDF
Supplementary Figure S2 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025
·
Jiali Quan
, Chunlan Zhuang
, et al.
PDF
Supplementary Table S3 from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025
·
Jiali Quan
, Chunlan Zhuang
, et al.
PDF
Data from Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody
2025
·
Jiali Quan
, Chunlan Zhuang
, et al.
Data from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
2024
·
Shifeng Lian
, Chenyu Lu
, et al.
Supplementary Figure S4 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
2024
·
Shifeng Lian
, Chenyu Lu
, et al.
Supplementary Table S2 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
2024
·
Shifeng Lian
, Chenyu Lu
, et al.
PDF
Supplementary Figure S2 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
2024
·
Shifeng Lian
, Chenyu Lu
, et al.
Supplementary Figure S1 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
2024
·
Shifeng Lian
, Chenyu Lu
, et al.
Supplementary Figure S3 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
2024
·
Shifeng Lian
, Chenyu Lu
, et al.
Supplementary Table S1 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
2024
·
Shifeng Lian
, Chenyu Lu
, et al.
Data from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
2024
·
Shifeng Lian
, Chenyu Lu
, et al.
20P Early detection and disease monitoring of hepatocellular carcinoma using circulating telomere DNA
2022
·
S. Lian
, C. Lu
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
24
Citation count:
56
H-index:
3
I10-index:
1
Year
Topic
Type
